Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion

INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.
Despite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.
Addressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.
By leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inovio Pharmaceuticals Inc.’s (NASDAQ: INO) Bill and Melinda Gates Foundation-backed DNA vaccine for the novel coronavirus enters human trials.

Inovio Pharmaceuticals Begins Phase 1 Human Testing Of Its COVID-19 Vaccine

The early study will only test whether INO-4800 is safe and triggers an immune response.

Inovio Pharmaceuticals Kicks Off Phase 1 Clinical Trial for Experimental COVID-19 Vaccine

The company started a clinical trial with its potential new COVID-19 vaccine.

Here's Why Inovio Pharmaceuticals Stock Jumped Today

Biotech firm Inovio Pharmaceuticals Inc. (NASDAQ: INO) announced Monday morning that the U.S.

Inovio to Begin Testing COVID-19 Vaccine

Inovio Pharmaceuticals Inc. INO, +2.92% is planning the first dosing of patients in a Phase 1 trial of its DNA vaccine candidate to treat COVID-19 on Monday, the company said in a statement.

Inovio Pharmaceuticals plans first dosing of patients in trial of DNA COVID-19 vaccine candiate on Monday

The small biotech has a promising pipeline that includes a potential COVID-19 vaccine. But is that enough to justify buying Inovio stock?

Should You Buy Inovio Pharmaceuticals During the Coronavirus Market Crash?

Ino stock has brought its COVID-19 vaccine to trial in record time. But for the stock to move higher, it needs to get the product to market.

Buying INO Stock Right Now Is More a Bet Than an Investment

GlaxoSmithKline

Johnson & Johnson

Moderna

Sanofi

Vaxart

Just like the flu vaccine, pharmacists should be empowered to administer the COVID-19 vaccine to patients in every state.

Expand Pharmacists’ Authority To Promote COVID-19 Vaccine Access

Biotech investing is tough. If you have a background in this space, sure, knock yourself out.

Look For Better Buys Than Coronavirus Play INO Stock

The company may be in line for more COVID-19 grant money.

Why Inovio Pharmaceuticals (INO) Stock Is Rising Today

Investors like the biotech's good news from a phase 2 clinical trial.

Why Inovio Pharmaceuticals Stock Soared Today

Gilead Sciences

Mylan

Novartis

Regeneron Pharmaceuticals

An old malaria drug may unseat newer investigational coronavirus treatments -- if data is confirmed.

3 Things to Know if Chloroquine Wins the COVID-19 Treatment Race

The results from its study of VGX-3100 are an encouraging signal that the biotech's coronavirus vaccine might work too.

Inovio Pharmaceuticals Reports Positive Trail Data for Cancer Vaccine

Biogen

Roche Holding AG

Vir Biotechnology

Given the urgent need for curing infected COVID-19 patients, let's take a look at the companies developing drugs/treatments for the same.

Biotech Stocks Accelerate Efforts for Coronavirus Treatments

INO stock has moved higher based on Inovio's hunt for a coronavirus vaccine. But this race also makes the pharmaceutical firm a one-dimensional investment.

Inovio Pharmaceuticals Will Fall Once Coronavirus Fears Fade

It is only a matter of time before this virus anxiety is a thing of the past.

Top 5 Drug Stocks To Stop The Coronavirus Pandemic

Inovio's Wild Ride And Real Value

A $11.9 million Defense Department grant will support the companies as they develop and test INO-4800.

Inovio Pharmaceuticals Gets Help From Ology Bioservices and the Defense Department with Its COVID-19 Vaccine Candidate

INO stock still has some serious upside, thanks to its INO-4800. Inovio's coronavirus vaccine takes the lead and is in preclinical trials.

Inovio Is Still Hot as the Coronavirus Spreads

Inovio could be a bargain using probability analysis. INO stock is cheap if there is a greater than 5% chance its COVID-19 vaccine will be successful.

Inovio Could Be a Bargain Using Probability Analysis

Inovio Pharmaceuticals Inc. INO, -8.31% and privately held Ology Bioservices Inc.

Inovio and Ology Bioservices awarded $11.9 million contract from DoD to work on COVID-19 vaccine

Inovio has a coronavirus vaccine candidate that has just entered testing, and INO stock speculators are going mad over it.
The post Inovio Rise is Today’s Sign of the Stockocalypse appeared first on InvestorPlace.

Inovio Rise is Today’s Sign of the Stockocalypse

Once an afterthought in the pharmaceutical space, INO stock suddenly looks interesting amid the coronavirus pandemic. However, it could also be a very temporary tailwind.

Can Inovio’s Vaccine Efforts Maintain Growth for INO Stock?

Bicycle Therapeutics Plc - ADR

Catalyst Pharmaceuticals

Amicus Therapeutics

Novavax

These five biotech stocks could post life-changing gains for early-bird investors.

5 Absurdly Cheap Biotech Stocks That Could Make You Filthy Rich

Both of these companies are in the thick of the hunt to develop a coronavirus vaccine. Which stock is the better pick right now?

News for Inovio Pharmaceuticals Stock (INO)